Given that we did not observe evidence of an overall effect of HbA1c (not caused by SGLT1 and SGLT2) on neurodegenerative disorders except for PD, the causal association of SGLT1i on ALS and MS, and SGLT2i on AD and MS, is unlikely to be related to glycemic control, and other mechanisms specific to SGLT1/2 may be driving the association. The gene discussed is SLC5A2; the disease is myeloid sarcoma.